237 related articles for article (PubMed ID: 26625870)
1. PLK2 phosphorylates and inhibits enriched TAp73 in human osteosarcoma cells.
Hu ZB; Liao XH; Xu ZY; Yang X; Dong C; Jin AM; Lu H
Cancer Med; 2016 Jan; 5(1):74-87. PubMed ID: 26625870
[TBL] [Abstract][Full Text] [Related]
2. PLK2 modulation of enriched TAp73 affects osteogenic differentiation and prognosis in human osteosarcoma.
Li W; Zhang X; Xi X; Li Y; Quan H; Liu S; Wu L; Wu P; Lan W; Shao Y; Li H; Chen K; Hu Z
Cancer Med; 2020 Jun; 9(12):4371-4385. PubMed ID: 32349184
[TBL] [Abstract][Full Text] [Related]
3. Polo-like kinase 2 acting as a promoter in human tumor cells with an abundance of TAp73.
Hu Z; Xu Z; Liao X; Yang X; Dong C; Luk K; Jin A; Lu H
Onco Targets Ther; 2015; 8():3475-88. PubMed ID: 26640387
[TBL] [Abstract][Full Text] [Related]
4. p73-mediated transcriptional activity is negatively regulated by polo-like kinase 1.
Soond SM; Barry SP; Melino G; Knight RA; Latchman DS; Stephanou A
Cell Cycle; 2008 May; 7(9):1214-23. PubMed ID: 18418051
[TBL] [Abstract][Full Text] [Related]
5. Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia.
Tonino SH; Mulkens CE; van Laar J; Derks IA; Suo G; Croon-de Boer F; van Oers MH; Eldering E; Wang JY; Kater AP
Leuk Lymphoma; 2015; 56(8):2439-47. PubMed ID: 25511680
[TBL] [Abstract][Full Text] [Related]
6. TAp73-mediated the activation of c-Jun N-terminal kinase enhances cellular chemosensitivity to cisplatin in ovarian cancer cells.
Zhang P; Liu SS; Ngan HY
PLoS One; 2012; 7(8):e42985. PubMed ID: 22900074
[TBL] [Abstract][Full Text] [Related]
7. CK2 phosphorylates and inhibits TAp73 tumor suppressor function to promote expression of cancer stem cell genes and phenotype in head and neck cancer.
Lu H; Yan C; Quan XX; Yang X; Zhang J; Bian Y; Chen Z; Van Waes C
Neoplasia; 2014 Oct; 16(10):789-800. PubMed ID: 25379016
[TBL] [Abstract][Full Text] [Related]
8. TAp73 promotes anabolism.
Amelio I; Antonov AA; Catani MV; Massoud R; Bernassola F; Knight RA; Melino G; Rufini A
Oncotarget; 2014 Dec; 5(24):12820-934. PubMed ID: 25514460
[TBL] [Abstract][Full Text] [Related]
9. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
[TBL] [Abstract][Full Text] [Related]
10. JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress.
Kostecka A; Sznarkowska A; Meller K; Acedo P; Shi Y; Mohammad Sakil HA; Kawiak A; Lion M; Królicka A; Wilhelm M; Inga A; Zawacka-Pankau J
Cell Death Dis; 2014 Oct; 5(10):e1484. PubMed ID: 25341038
[TBL] [Abstract][Full Text] [Related]
11. Runt-related transcription factor 2 attenuates the transcriptional activity as well as DNA damage-mediated induction of pro-apoptotic TAp73 to regulate chemosensitivity.
Ozaki T; Sugimoto H; Nakamura M; Hiraoka K; Yoda H; Sang M; Fujiwara K; Nagase H
FEBS J; 2015 Jan; 282(1):114-28. PubMed ID: 25331851
[TBL] [Abstract][Full Text] [Related]
12. TAp73 promotes anti-senescence-anabolism not proliferation.
Agostini M; Niklison-Chirou MV; Catani MV; Knight RA; Melino G; Rufini A
Aging (Albany NY); 2014 Nov; 6(11):921-30. PubMed ID: 25554796
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of p73 variants in response to cisplatin treatment in SH-SY5Y neuroblastoma cells.
Million K; Horvilleur E; Goldschneider D; Agina M; Raguénez G; Tournier F; Bénard J; Douc-Rasy S
Int J Oncol; 2006 Jul; 29(1):147-54. PubMed ID: 16773194
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation.
Koida N; Ozaki T; Yamamoto H; Ono S; Koda T; Ando K; Okoshi R; Kamijo T; Omura K; Nakagawara A
J Biol Chem; 2008 Mar; 283(13):8555-63. PubMed ID: 18174154
[TBL] [Abstract][Full Text] [Related]
15. Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function.
Watson IR; Blanch A; Lin DC; Ohh M; Irwin MS
J Biol Chem; 2006 Nov; 281(45):34096-103. PubMed ID: 16980297
[TBL] [Abstract][Full Text] [Related]
16. Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells.
Dar AA; Belkhiri A; Ecsedy J; Zaika A; El-Rifai W
Cancer Res; 2008 Nov; 68(21):8998-9004. PubMed ID: 18974145
[TBL] [Abstract][Full Text] [Related]
17. p53 inactivation upregulates p73 expression through E2F-1 mediated transcription.
Tophkhane C; Yang SH; Jiang Y; Ma Z; Subramaniam D; Anant S; Yogosawa S; Sakai T; Liu WG; Edgerton S; Thor A; Yang X
PLoS One; 2012; 7(8):e43564. PubMed ID: 22952705
[TBL] [Abstract][Full Text] [Related]
18. TAp73 induction by nitric oxide: regulation by checkpoint kinase 1 (CHK1) and protection against apoptosis.
Tebbi A; Guittet O; Cottet MH; Vesin MF; Lepoivre M
J Biol Chem; 2011 Mar; 286(10):7873-7884. PubMed ID: 21212274
[TBL] [Abstract][Full Text] [Related]
19. Ribosomal proteins L11 and L5 activate TAp73 by overcoming MDM2 inhibition.
Zhou X; Hao Q; Zhang Q; Liao JM; Ke JW; Liao P; Cao B; Lu H
Cell Death Differ; 2015 May; 22(5):755-66. PubMed ID: 25301064
[TBL] [Abstract][Full Text] [Related]
20. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions.
Matthew EM; Hart LS; Astrinidis A; Navaraj A; Dolloff NG; Dicker DT; Henske EP; El-Deiry WS
Cell Cycle; 2009 Dec; 8(24):4168-75. PubMed ID: 20054236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
